[CYTX] Cytori Therapeutics Inc

Overview

Type of security: Stock

Sector: Health Care

Industry: Medical/Dental Instruments

Market Capitalization: 39.28 M

Exchange: NASDAQ

The data is delayed by 15 minutes.

 

Price: 1.49 Change: 0.01 (0.68%)
Ext. hours: Change: 0 (0%)

chart CYTX

Refresh chart

Strongest Trends Summary For CYTX

CYTX is in the medium-term down -32% below S&P in 5 months. In the long-term down -91% below S&P in 1 year and down -100% below S&P in 10 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: Cytori Therapeutics, Inc., a cell therapy company, develops cell therapies based on autologous adipose-derived regenerative cells (ADRCs) to treat cardiovascular disease and other medical conditions. It primarily provides the Celution System, a tissue processing system that automates the process of digesting fat tissue, releasing the ADRCs. The company also offers the StemSource Cell Bank, a suite of products to allow hospitals or tissue banks to cryopreserve adipose-derived stem and regenerative cells; and StemSource 900/MB, a research laboratory equipment. Its products also include Celution 800 System that has CE Mark approval for certain soft tissue procedures, such as breast reconstruction, tissue ischemia, deficiency or injury of skin, fat, and muscle and fascia, as well as soft tissue wounds or fistulae associated with trauma, diabetes, ischemia, and radiation injury. In addition, Cytori Therapeutics, Inc. develops products in therapeutic areas, such as the treatment of thermal burns, and orthopedics an

Fundamental Ratios
Shares Outstanding20.04 M EPS EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters 81.86% Sales Growth - Q/Q-37.76% P/E
P/E To EPS Growth P/S4.62 P/BV-1.69 Price/Cash Per Share
Price/Free Cash Flow-1.26 ROA-132.07% ROE210.93% ROI
Current Ratio1.06 Quick Ratio0.82 Long Term Debt/Equity13.53 Debt Ratio-0.81
Gross Margin63.37% Operating Margin-515.71% Net Profit Margin-574.92% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities3.78 M Cash From Investing Activities-190 K Cash From Operating Activities-5.03 M Gross Profit1.75 M
Net Profit-21.96 M Operating Profit-21 M Total Assets37.05 M Total Current Assets19.86 M
Total Current Liabilities18.7 M Total Debt28.77 M Total Liabilities60.24 M Total Revenue2.35 M
Technical Data
High 52 week2.79 Low 52 week0.24 Last close0.24 Last change-5.66%
RSI23.37 Average true range0.03 Beta0.99 Volume105.52 K
Simple moving average 20 days-14.62% Simple moving average 50 days-14.85% Simple moving average 200 days-62.43%
Performance Data
Performance Week-9.43% Performance Month-23.54% Performance Quart-9.6% Performance Half-54.29%
Performance Year-38.19% Performance Year-to-date-17.24% Volatility daily3.14% Volatility weekly7.01%
Volatility monthly14.37% Volatility yearly49.77% Relative Volume114.7% Average Volume684.63 K
New High New Low

News

2019-07-16 16:15:00 | Cytori Will Become Plus Therapeutics, Inc.

2019-07-12 11:48:58 | Should You Worry About Cytori Therapeutics, Inc.'s NASDAQ:CYTX CEO Pay Cheque?

2019-07-11 20:00:00 | Cytori to Present Corporate Update & New Strategic Direction

2019-07-05 09:39:51 | Cytori CFO Resigns, Biotech Restructures In Bid To Focus Resources On Lung Cancer Drug

2019-07-01 08:30:00 | Cytori Reports Summary of FDA Feedback Regarding its ATI-1123 Product

2019-06-27 17:10:00 | Cytori Announces New Annual Stockholders Meeting Date for July 11

2019-06-19 13:15:02 | Cytori Announces New Annual Stockholders Meeting Date for June 27

2019-06-13 10:43:14 | Cytori to Present New Strategic Direction

2019-05-30 16:15:00 | Cytori Announces New Annual Stockholders Meeting Date for June 18

2019-05-14 17:37:17 | Cytori: 1Q Earnings Snapshot

2019-05-14 16:50:00 | Cytori Reports Q1 2019 Business and Financial Results

2019-04-23 08:05:00 | Japan Cell Therapy Transaction Yields $3MM

2019-04-09 09:53:45 | Analysts Expect Breakeven For Cytori Therapeutics, Inc. NASDAQ:CYTX

2019-04-01 15:46:41 | Edited Transcript of CYTX earnings conference call or presentation 1-Apr-19 12:30pm GMT

2019-04-01 09:34:20 | Cytori: 4Q Earnings Snapshot

2019-04-01 08:05:00 | Cytori Reports Fourth Quarter and Full Year 2018 Business and Financial Results

2019-03-29 08:00:00 | Cytori to Webcast Fourth Quarter and 2018 Financial Results on April 1

2019-03-07 08:30:00 | Cytori Files Pre-submission Request for New Drug Application

2019-01-31 08:30:00 | Cytori Cell Therapy™ Clinical Trial Results in Crohn’s Disease

2019-01-22 14:01:21 | Does Cytori Therapeutics, Inc. NASDAQ:CYTX Have A High Beta?

2018-12-30 15:27:08 | The Week Ahead In Biotech: Conferences, PDUFA Dates And Clinical Trials

2018-12-03 10:48:27 | Shares Of Penny Stock Cytori Rise On Japanese Device Approval

2018-12-03 07:30:00 | Cytori Announces Japan Class III Medical Device Approval for Cell Therapy Product

2018-11-15 01:26:16 | Edited Transcript of CYTX earnings conference call or presentation 14-Nov-18 10:30pm GMT

2018-11-14 18:45:11 | Cytori Therapeutics CYTX Reports Q3 Loss, Misses Revenue Estimates

2018-11-14 17:37:16 | Cytori: 3Q Earnings Snapshot

2018-11-14 16:15:00 | Cytori Reports Q3 2018 Business and Financial Results

2018-11-09 08:30:00 | Cytori to Webcast Third Quarter Financial Results on November 14

2018-10-30 09:28:00 | Cytori Therapeutics Announces Receipt of Puregraft® Royalty Milestone

2018-09-26 15:02:37 | Cytori Therapeutics Inc NASDAQ:CYTX Is Expected To Breakeven

2018-09-18 08:50:12 | Cytori's Chemotherapy Candidate Gets Orphan Drug Status

2018-09-17 09:28:00 | Phase 2 Ready Oncology Drug Receives FDA Orphan Drug Designation

2018-08-31 09:00:00 | Cytori Therapeutics to Present at the 20th Annual Rodman & Renshaw Global Investment Conference

2018-08-16 09:37:07 | The Daily Biotech Pulse: No Anxiety For Biohaven, Strongbridge's About-Face, Bristol-Myers Squibb's FDA Wait

2018-08-15 08:48:49 | The Daily Biotech Pulse: Vertex Awaits FDA Verdict, Strongbridge Falls On Offering, ReShape's Woes Continue

2018-08-14 21:45:35 | Edited Transcript of CYTX earnings conference call or presentation 14-Aug-18 9:30pm GMT

2018-08-14 17:47:11 | Cytori: 2Q Earnings Snapshot

2018-08-14 16:20:00 | Cytori Reports Q2 2018 Business and Financial Results

2018-08-14 08:23:00 | The Daily Biotech Pulse: Cesca, Acer Therapeutics Rally On Earnings, Aridis Makes Its Nasdaq Debut

2018-08-09 09:25:00 | Cytori Reports Publication of Interim Pilot Data for Cell Therapy in Vocal Fold Scarring

2018-08-02 16:01:00 | Cytori to Webcast Second Quarter Financial Results on August 14

2018-07-24 07:01:00 | Cytori Announces $6.7 Million in Expected Gross Proceeds from Recently Expired Rights Offering

2018-07-16 08:30:00 | Cytori Reminds Stockholders That Rights Offering Expires on Friday, July 20

2018-07-09 00:00:00 | Cytori Reports Sustained Benefit of Cell Therapy in Erectile Dysfunction Trial

2018-06-28 09:00:00 | Cytori Reports Improved Skin Healing in Pivotal Burn Preclinical Study

2018-06-27 08:14:48 | Benzinga's Daily Biotech Pulse: Pain Therapeutics Drops 70%, Neon To Begin Trading

2018-06-22 12:00:00 | Cytori Therapeutics Reminds Investors of Today’s Deadline to be a Shareholder of Record

2018-06-12 08:30:00 | Cytori Informs Stockholders of Key Dates and Terms Related to Announced Rights Offering

2018-05-25 15:37:17 | Cytori Therapeutics Inc NASDAQ:CYTX: Are Analysts Optimistic?

2018-05-24 08:37:35 | Benzinga's Daily Biotech Pulse: Eiger And Melinta Fall On Offerings, Apellis And Marinus Rise On Bullish Ratings